

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
19 March 2020 (19.03.2020)



(10) International Publication Number
WO 2020/056085 A1

- (51) **International Patent Classification:**
C07K 14/705 (2006.01) *A61K 38/17* (2006.01)
- (21) **International Application Number:**
PCT/US2019/050742
- (22) **International Filing Date:**
12 September 2019 (12.09.2019)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
62/731,488 14 September 2018 (14.09.2018) US
62/888,320 16 August 2019 (16.08.2019) US
- (71) **Applicants: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY** [US/US]; Office of the General Counsel, Building 170, Third Floor, Main Quad, P.O. Box 20386, Stanford, California 94305-2038 (US). **AKSO BIOPHARMACEUTICAL, INC.** [US/US]; 2730 Sand Hill Road, Suite 230, Menlo Park, California 94025 (US).
- (72) **Inventors: GIACCIA, Amato J.**; c/o Leland Stanford University, Building 170, Third Floor, Main Quad, Stanford, California 94305 (US). **AGUILERA, Todd A.**; c/o Leland Stanford University, Building 170, Third Floor, Main Quad, Stanford, California 94305 (US). **KAROLIS, Mihalios S.**; c/o Leland Stanford University, Building 170, Third Floor, Main Quad, Stanford, California 94305 (US). **MIAO, Yu**; c/o Leland Stanford University, Building 170, Third Floor, Main Quad, Stanford, California 94305 (US). **THAKKAR, Kaushik**; c/o Leland Stanford University, Building 170, Third Floor, Main Quad, Stanford, California 94305 (US). **ZHANG, Xin Eric**; c/o AKSO Biopharm-

aceutical, Inc., 2730 Sand Hill Road, Suite 230, Menlo Park, California 94025 (US).

- (74) **Agent: HAO, Joe C.** et al.; Kilpatrick Townsend & Stockton LLP, Mailstop: IP Docketing - 22, 1100 Peachtree Street, Suite 2800, Atlanta, GA 30309 (US).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

— with international search report (Art. 21(3))

(54) **Title:** SPD-1 VARIANT - FC FUSION PROTEINS

FIG. 8



Analyte	Ligand	ka (1/Ms)	kd (1/s)	KD (M)
Human PD-L1	s-h-PD1-ECD-Fc version 1	1.03E+6	6.94E-4	3.40E-10
	s-h-PD1-ECD-Fc version 2	2.13E+6	7.50E-4	3.42E-10
	s-h-PD1-ECD-Fc	N/A	N/A	2.74E-6
Human PD-L2	s-h-PD1-ECD-Fc version 1	4.36E+6	0.01288	2.94E-9
	s-h-PD1-ECD-Fc version 2	4.47E+6	0.01524	3.40E-9
	s-h-PD1-ECD-Fc	1.81E+5	0.1029	5.47E-7

(57) **Abstract:** The invention is directed to novel SPD-1 variant - Fc fusion proteins.

WO 2020/056085 A1